JP4322933B2 - チロシンキナーゼ阻害剤が惹起する皮膚障害の予防剤および/または処置剤 - Google Patents
チロシンキナーゼ阻害剤が惹起する皮膚障害の予防剤および/または処置剤 Download PDFInfo
- Publication number
- JP4322933B2 JP4322933B2 JP2007060415A JP2007060415A JP4322933B2 JP 4322933 B2 JP4322933 B2 JP 4322933B2 JP 2007060415 A JP2007060415 A JP 2007060415A JP 2007060415 A JP2007060415 A JP 2007060415A JP 4322933 B2 JP4322933 B2 JP 4322933B2
- Authority
- JP
- Japan
- Prior art keywords
- tyrosine kinase
- kinase inhibitor
- agent
- egfr tyrosine
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
また、アスピリン併用群で副作用の発生が少なかった(表2)。ゲフィチニブ単独投与群とアスピリン併用群での、副作用発現の比較(ゲフィチニブ単独投与群vsアスピリン併用群)は次の通りであり、全副作用:77.8% vs 58.3%、皮膚障害:74.1% vs 33.3%、下痢:18.5% vs 0%(表2)であった。効果について両群で明らかな違いはなかった(37.0 vs 33.3%)(表1)。
sP-selectin:可溶性P-セレクチン
*:p<0.05
**:p<0.01
***:p<0.001
N.S.:有意差なし
Claims (5)
- 80−100mgのアセチルサリチル酸(アスピリン)と上皮成長因子受容体(以下、EGFR)チロシンキナーゼ阻害剤を有効成分として含有する抗癌剤。
- EGFRチロシンキナーゼ阻害剤が、ゲフィチニブ、エルロチニブ、CI1033、PKI166、GW2016、EKB569、C225、ABX−EGF、EMD−72000およびMDX−447からなる群から選択される、請求項1に記載の抗癌剤。
- EGFRチロシンキナーゼ阻害剤が、抗EGFR抗体である、請求項1に記載の抗癌剤。
- 癌が、非小細胞肺癌である、請求項1−3のいずれかに記載の抗癌剤。
- ゲフィチニブが250mg/回/日で経口投与されるように設計された、請求項1、2および4のいずれかに記載の抗癌剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007060415A JP4322933B2 (ja) | 2007-03-09 | 2007-03-09 | チロシンキナーゼ阻害剤が惹起する皮膚障害の予防剤および/または処置剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007060415A JP4322933B2 (ja) | 2007-03-09 | 2007-03-09 | チロシンキナーゼ阻害剤が惹起する皮膚障害の予防剤および/または処置剤 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006073022A Division JP4091639B2 (ja) | 2006-03-16 | 2006-03-16 | チロシンキナーゼ阻害剤が惹起する皮膚障害の予防剤および/または処置剤 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2007246523A JP2007246523A (ja) | 2007-09-27 |
JP2007246523A5 JP2007246523A5 (ja) | 2009-01-08 |
JP4322933B2 true JP4322933B2 (ja) | 2009-09-02 |
Family
ID=38591186
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007060415A Expired - Fee Related JP4322933B2 (ja) | 2007-03-09 | 2007-03-09 | チロシンキナーゼ阻害剤が惹起する皮膚障害の予防剤および/または処置剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4322933B2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105311029A (zh) * | 2014-06-06 | 2016-02-10 | 正大天晴药业集团股份有限公司 | 抗肿瘤活性的喹啉衍生物 |
-
2007
- 2007-03-09 JP JP2007060415A patent/JP4322933B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2007246523A (ja) | 2007-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Knox et al. | A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix | |
AU2013299841B2 (en) | Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor | |
CA3057969A1 (en) | Combination therapy | |
US20180042891A1 (en) | Cancer Cell Apoptosis | |
CA2868677A1 (en) | Dexanabinol or a derivative thereof for use in the treatment of cancer in dose ranges of 2-30 mg/kg | |
JP6826737B2 (ja) | がん患者の治療に有用な尿のアルカリ剤 | |
JP4091639B2 (ja) | チロシンキナーゼ阻害剤が惹起する皮膚障害の予防剤および/または処置剤 | |
JP4322933B2 (ja) | チロシンキナーゼ阻害剤が惹起する皮膚障害の予防剤および/または処置剤 | |
JP2023065622A (ja) | 重度腎機能障害を有する癌患者に対する治療方法 | |
SG191926A1 (en) | Combinations | |
US20070269531A1 (en) | Non-Steroid Anti-Inflammatory Agents with Vitamins, Minerals, and Dietary Supplements for the Prevention and Treatment of Primary, Secondary and Tertiary Cancer | |
CA3124316C (en) | Cancer treatment using docetaxel by controlling peak plasma levels | |
JP7223998B2 (ja) | Axl阻害剤を有効成分として含む固形がん治療剤 | |
KR20230027226A (ko) | 화학요법-유발 설사를 치료하기 위한 방법 및 조성물 | |
CN114177299B (zh) | 包含ezh2抑制剂和scd1抑制剂的抗肿瘤药物组合物及其用途 | |
JP2007246523A5 (ja) | ||
KR102528732B1 (ko) | 포지오티닙 및 칼슘채널 억제제를 포함하는 암의 예방 또는 치료용 약학적 조성물 | |
CN106176757B (zh) | 一种化合物与替吉奥联合在制备治疗增生性疾病中的药物中的用途 | |
WO2020045461A1 (ja) | ピラゾロ[3,4-d]ピリミジン化合物を有効成分とする治療剤 | |
WO2021081081A1 (en) | Methods of treating, ameliorating, and/or preventing cancer using pyrvinium compositions | |
JP2019131559A (ja) | 頭頚部がんの処置または予防において使用されるpi3キナーゼ阻害剤とパクリタキセルの組合せ | |
NZ788180A (en) | Combination therapy with notch and pd-1 or pd-l1 inhibitors | |
JP2011116728A (ja) | 膵癌に対するラパチニブとts−1の併用療法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081117 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081117 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20081117 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20081211 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081224 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090526 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090603 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4322933 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120612 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150612 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |